Experiment Proposal (crux): Selective Acid Sphingomyelinase Modulation Therapy — Causal relationship between ASM elevation and disease initiation remains unprove

AIMS

HYPOTHESES

PROTOCOL SUMMARY

Cohort 1 (Necessity Test): Cross Smpd1-floxed mice with 5xFAD mice; treat with either vehicle, amitriptyline (non-selective), or selective ASM inhibitor (20mg/kg/day i.p.) at pre-symptomatic age (8 weeks). Monitor: (a) ASM activity assay in brain homogenates (Amplex Red ceramide substrate), (b) longitudinal PET imaging of neuroinflammation [11C]-PK11195, (c) cognitive behavioral testing monthly, (d) survival endpoint histology for amyloid burden, neuronal count (NeuN), lysosomal markers (Lamp2). n=30 per group. Cohort 2 (Sufficiency Test): Generate Smpd1-LSL;CamMKIIa-CreERT2 mice. At 8 weeks, induce ASM overexpression via tamoxifen (75mg/kg i.p. 5 consecutive days). Controls: Smpd1-LSL without Cre (overexpression absent), Cre-only (tamoxifen effects). Endpoints at 4, 12, 24 weeks post-induction: (a) SMPD1 activity assay, (b) ceramide quantitation by LC-MS/MS (brain regions), (c) EM for lysosomal morphology, (d)GFAP/Iba1 immunohistochemistry for gliosis, (e) caspase-3 activity assay, (f) cognitive testing. Cohort 3 (Temporal Specificity): Smpd1-LSL;GFAP-CreERT2 mice crossed to Tau P301S. Perform tamoxifen at different time windows (pre vs. post tau pathology onset). Serial CSF sampling for neurofilament light chain (NfL) as biomarker. Endpoint analysis includes tau phosphorylation (AT8), neurofilament accumulation, behavioral decline. Cohort 4 (Human iPSC Validation): Cerebral organoids from ASM-deficient (Niemann-Pick A) and NPD heterozygote lines, vs. isogenic CRISPR-corrected controls. Lentiviral SMPD1 overexpression to model elevated states. 90-day differentiation with longitudinal mass spectrometry for lipid species, confocal imaging for lysosomal pH (ratiometric dextran sensor), Seahorse XF for bioenergetics, RNA-seq at day 60 and 90. Statistical design: Two-way ANOVA with Bonferroni correction for behavioral data; Kaplan-Meier with log-rank for survival; Spearman correlation for biomarker temporal relationships. Pre-registered power analysis targets d=0.8 at α=0.05.

PREDICTED OBSERVATIONS

If ASM elevation is necessary: Cohort 1 will show selective ASM inhibitor significantly reduces neuroinflammation and cognitive decline in 5xFAD mice compared to vehicle, with amitriptyline showing intermediate effect due to off-target actions. Amyloid burden may be unchanged (confirming ASM acts downstream of amyloid), but lysosomal integrity and neuronal survival improve. If ASM elevation is sufficient: Cohort 2 will show ASM overexpression alone causes progressive ceramide accumulation, lysosomal swelling, microglial activation, and cognitive decline in otherwise healthy mice by 24 weeks. Lysosomal pH will be elevated (deacidified). No amyloid or tau pathology will emerge, confirming ASM-mediated damage operates independently. If temporal specificity exists: Cohort 3 will show ASM elevation during pre-symptomatic window accelerates neurodegeneration (NfL elevation precedes behavioral decline), while post-pathology ASM modulation is less effective, establishing a therapeutic window. If ASM elevation is neither necessary nor sufficient: Cohort 1 will show no benefit from ASM inhibition; Cohort 2 will show no neurodegeneration despite ASM elevation; effect sizes will be nil or confounded by off-target actions.

FALSIFICATION CRITERIA

The causal hypothesis will be considered falsified if: (1) In Cohort 1, selective ASM inhibition fails to alter neurodegeneration trajectory despite confirmed enzyme inhibition (>70% reduction in activity); (2) In Cohort 2, ASM overexpression sufficient to cause >3-fold elevation in brain ceramide does NOT produce any measurable neurodegenerative phenotype at 24 weeks (defined as <10% change in neuronal count, no gliosis above baseline, no behavioral impairment); (3) ASM elevation in Cohort 2 occurs without preceding lysosomal dysfunction, suggesting ASM is downstream of lysosomal damage rather than upstream initiator; (4) In Cohort 4, human cerebral organoids with SMPD1 overexpression fail to reproduce neurodegenerative phenotypes observed in rodent models, suggesting species-specificity undermines therapeutic translation; (5) Amitriptyline and selective inhibitor show identical effect profiles, indicating ASM is not the relevant target. Conversely, the null hypothesis (no causality) is falsified if: (a) ASM inhibition prevents disease in Cohort 1 AND ASM overexpression causes disease in Cohort 2, both with dose-response relationships; (b) temporal removal of ASM (genetic knockout after disease onset) halts progression in Cohort 3; (c) human iPSC models replicate the directionality observed in mouse models.

DATASET DEPENDENCIES